<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865473</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-010915</org_study_id>
    <nct_id>NCT02865473</nct_id>
  </id_info>
  <brief_title>Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study</brief_title>
  <official_title>Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and Pseudoexfoliation Syndrome - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      The aim of the present study is to develop a measurement protocol for optimal imaging of the
      anterior segment of the eye, including anterior chamber angle, Schlemm's canal, filtering
      bleb and pseudoexfoliation deposits on the lens based on measurements in patients with
      glaucoma and PEX. In glaucoma the structures of the anterior chamber are important for
      classification, therapy, progression and prognosis and imaging of the angle between the iris
      and the cornea is the key for open angle and closed angle glaucoma differential diagnosis.
      For this purpose, a customized ultrahigh resolution Spectral Domain OCT will be used to
      validate whether the protocol can also be more widely applied in these patients. Based on the
      obtained measurement protocol, further studies investigating anatomy and pathophysiology of
      the anterior segment of the eye as well as surgical outcome in patients with glaucoma and PEX
      can be planned.

      The aim of the study is to develop a measurement protocol for OCT imaging and
      characterization of the anterior chamber in glaucoma patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-dimensional imaging of the anterior eye segment</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>primary open angle glaucoma patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with primary angle closure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with neovascular glaucoma</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PEX glaucoma patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glaucoma patients with filtering bleb</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>instillation of antiglaucoma treatment in the study eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>topical instillation into the study eye</description>
    <arm_group_label>healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged over 18 years

        For patients with primary open angle glaucoma:

          -  Diagnosed primary open angle glaucoma

          -  Visual field defects and optic nerve head appearance characteristic for glaucoma

          -  Open anterior chamber angle as evidenced by gonioscopy

          -  No previous glaucoma surgery

          -  No previous cataract surgery

        For patients with primary angle closure:

          -  Angle closure predisposition as evidenced from goniosocopy

          -  No previous glaucoma surgery

        For patients with neovascular glaucoma:

        - Neovascularization in the anterior chamber angle

        For patients with pseudoexfolation deposits on the lens:

          -  PEX glaucoma as evidenced from slit lamp examination

          -  Visual field defects and optic nerve head appearance characteristic for glaucoma

          -  Open anterior chamber angle as evidenced by gonioscopy

          -  No previous glaucoma or cataract surgery

        For glaucoma patients with filtering bleb after trabeculectomy:

          -  Patients with history of trabeculectomy secondary to open angle glaucoma in the
             previous three months

          -  No cataract surgery

        For healthy volunteers:

          -  No evidence of ocular disease

          -  No degenerative changes in the retina in funduscopy after mydriasis

          -  Ametropia less than 3 dpt.

        Exclusion Criteria:

          -  Presence of any abnormalities preventing reliable measurements as judged by the
             investigator

          -  Pregnancy, planned pregnancy or lactating

          -  Ocular inflammation and ocular disease interfering with the study aims as judged by
             the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerhard Garhöfer, Assoc. Prof. PD Dr.</last_name>
    <phone>0043140400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhöfer, Assoc. Prof. PD Dr.</last_name>
      <phone>0043140400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Sabina Sapeta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>René Werkmeister, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doreen Schmidl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Bata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piotr Wozniak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klemens Fondi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leopold Schmetterer, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <keyword>Schlemm's canal lumen area</keyword>
  <keyword>PEX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

